JP2019511506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511506A5 JP2019511506A5 JP2018550539A JP2018550539A JP2019511506A5 JP 2019511506 A5 JP2019511506 A5 JP 2019511506A5 JP 2018550539 A JP2018550539 A JP 2018550539A JP 2018550539 A JP2018550539 A JP 2018550539A JP 2019511506 A5 JP2019511506 A5 JP 2019511506A5
- Authority
- JP
- Japan
- Prior art keywords
- ofatumumab
- pharmaceutical composition
- administering
- multiple sclerosis
- regimen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002450 ofatumumab Drugs 0.000 claims description 16
- 238000009472 formulation Methods 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 238000012423 maintenance Methods 0.000 claims 6
- 201000006417 multiple sclerosis Diseases 0.000 claims 6
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 4
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 2
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 2
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 2
- 238000010254 subcutaneous injection Methods 0.000 claims 2
- 239000007929 subcutaneous injection Substances 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940090047 auto-injector Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940071643 prefilled syringe Drugs 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 1
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 description 1
- 229960000331 teriflunomide Drugs 0.000 description 1
- 229940057406 teriflunomide 14 mg Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662374986P | 2016-08-15 | 2016-08-15 | |
| US62/374,986 | 2016-08-15 | ||
| PCT/IB2017/054909 WO2018033841A1 (en) | 2016-08-15 | 2017-08-11 | Regimens and methods of treating multiple sclerosis using ofatumumab |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020019337A Division JP7198786B2 (ja) | 2016-08-15 | 2020-02-07 | オファツムマブを用いた多発性硬化症の治療レジメンおよび治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511506A JP2019511506A (ja) | 2019-04-25 |
| JP2019511506A5 true JP2019511506A5 (https=) | 2020-04-09 |
| JP6851391B2 JP6851391B2 (ja) | 2021-03-31 |
Family
ID=59901554
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550539A Active JP6851391B2 (ja) | 2016-08-15 | 2017-08-11 | オファツムマブを用いた多発性硬化症の治療レジメンおよび治療方法 |
| JP2020019337A Active JP7198786B2 (ja) | 2016-08-15 | 2020-02-07 | オファツムマブを用いた多発性硬化症の治療レジメンおよび治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020019337A Active JP7198786B2 (ja) | 2016-08-15 | 2020-02-07 | オファツムマブを用いた多発性硬化症の治療レジメンおよび治療方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US11161909B2 (https=) |
| EP (5) | EP3497132B1 (https=) |
| JP (2) | JP6851391B2 (https=) |
| KR (2) | KR20190038914A (https=) |
| CN (5) | CN120053638A (https=) |
| AU (2) | AU2017311664C1 (https=) |
| CA (2) | CA3030530C (https=) |
| CY (1) | CY1123350T1 (https=) |
| DE (1) | DE202017007542U1 (https=) |
| DK (2) | DK3497132T3 (https=) |
| ES (2) | ES2954259T3 (https=) |
| FI (1) | FI3733712T3 (https=) |
| HR (2) | HRP20230894T1 (https=) |
| HU (2) | HUE051948T2 (https=) |
| IL (4) | IL302488B2 (https=) |
| LT (2) | LT3497132T (https=) |
| MX (1) | MX388593B (https=) |
| PL (2) | PL3497132T3 (https=) |
| PT (2) | PT3497132T (https=) |
| RS (2) | RS64541B1 (https=) |
| RU (1) | RU2749951C2 (https=) |
| SI (2) | SI3497132T1 (https=) |
| TW (1) | TWI752995B (https=) |
| WO (1) | WO2018033841A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120053638A (zh) * | 2016-08-15 | 2025-05-30 | 诺华股份有限公司 | 使用奥法木单抗治疗多发性硬化的方案和方法 |
| ES2957112T3 (es) | 2019-09-11 | 2024-01-11 | Novartis Ag | Tratamiento del RMS mediante cambio de terapia |
| MX2022003030A (es) | 2019-09-11 | 2022-04-07 | Novartis Ag | Tratamiento de afecciones distintas de la esclerosis multiple en pacientes tratados con ofatumumab. |
| US20230151106A1 (en) * | 2020-04-09 | 2023-05-18 | Novartis Ag | OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG |
| US20240228647A1 (en) * | 2021-04-14 | 2024-07-11 | Novartis Ag | Ofatumumab for treating multiple sclerosis in asian patients |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4816401A (en) | 1985-09-09 | 1989-03-28 | University Of Rochester | Serum free cell culture medium |
| JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| JP2003529361A (ja) | 2000-03-30 | 2003-10-07 | アムジェン インコーポレイテッド | ＣＤ２０／ＩｇＥレセプター様分子およびその使用 |
| EA013564B1 (ru) | 2000-08-03 | 2010-06-30 | Терапеутик Хьюман Поликлоналз Инк. | Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция |
| CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| DOP2006000029A (es) | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
| WO2012018704A1 (en) | 2010-08-02 | 2012-02-09 | Sanofi-Aventis U.S. Llc | Use of teriflunomide for treating multiple sclerosis |
| EP2663331A4 (en) | 2011-01-10 | 2015-07-15 | Glaxosmithkline Intellectual Property Man Ltd | NEW USES |
| TWI606064B (zh) * | 2012-02-08 | 2017-11-21 | Ｉｇｍ生物科技公司 | 細胞死亡誘導分子（ｃｄｉｍ）結合蛋白類及彼等之用途 |
| EP2692343A1 (en) | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| SG11201500499TA (en) | 2012-08-10 | 2015-03-30 | Boehringer Ingelheim Int | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
| WO2015162504A1 (en) | 2014-04-23 | 2015-10-29 | Novartis Ag | Novel dosing and uses of ofatumumab |
| EA201692180A1 (ru) | 2014-04-29 | 2017-08-31 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации |
| WO2016123329A2 (en) * | 2015-01-28 | 2016-08-04 | Genentech, Inc. | Gene expression markers and treatment of multiple sclerosis |
| CN106699886A (zh) | 2015-07-13 | 2017-05-24 | 西藏海思科药业集团股份有限公司 | 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体 |
| CN120053638A (zh) | 2016-08-15 | 2025-05-30 | 诺华股份有限公司 | 使用奥法木单抗治疗多发性硬化的方案和方法 |
| ES2957112T3 (es) | 2019-09-11 | 2024-01-11 | Novartis Ag | Tratamiento del RMS mediante cambio de terapia |
| MX2022003030A (es) | 2019-09-11 | 2022-04-07 | Novartis Ag | Tratamiento de afecciones distintas de la esclerosis multiple en pacientes tratados con ofatumumab. |
| US20230151106A1 (en) | 2020-04-09 | 2023-05-18 | Novartis Ag | OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG |
| US20240228647A1 (en) | 2021-04-14 | 2024-07-11 | Novartis Ag | Ofatumumab for treating multiple sclerosis in asian patients |
| IL310813A (en) | 2021-08-16 | 2024-04-01 | Novartis Ag | OFATUMUMAB for the treatment of multiple sclerosis in children |
-
2017
- 2017-08-11 CN CN202510270941.5A patent/CN120053638A/zh active Pending
- 2017-08-11 PT PT177688637T patent/PT3497132T/pt unknown
- 2017-08-11 KR KR1020197007454A patent/KR20190038914A/ko not_active Ceased
- 2017-08-11 EP EP17768863.7A patent/EP3497132B1/en active Active
- 2017-08-11 EP EP23172507.8A patent/EP4252847A3/en active Pending
- 2017-08-11 LT LTEP17768863.7T patent/LT3497132T/lt unknown
- 2017-08-11 HU HUE17768863A patent/HUE051948T2/hu unknown
- 2017-08-11 WO PCT/IB2017/054909 patent/WO2018033841A1/en not_active Ceased
- 2017-08-11 RU RU2019107146A patent/RU2749951C2/ru active
- 2017-08-11 MX MX2019001860A patent/MX388593B/es unknown
- 2017-08-11 FI FIEP20180938.1T patent/FI3733712T3/fi active
- 2017-08-11 DE DE202017007542.3U patent/DE202017007542U1/de active Active
- 2017-08-11 EP EP20180938.1A patent/EP3733712B1/en active Active
- 2017-08-11 HR HRP20230894TT patent/HRP20230894T1/hr unknown
- 2017-08-11 CA CA3030530A patent/CA3030530C/en active Active
- 2017-08-11 RS RS20230635A patent/RS64541B1/sr unknown
- 2017-08-11 IL IL302488A patent/IL302488B2/en unknown
- 2017-08-11 AU AU2017311664A patent/AU2017311664C1/en active Active
- 2017-08-11 ES ES20180938T patent/ES2954259T3/es active Active
- 2017-08-11 PL PL17768863T patent/PL3497132T3/pl unknown
- 2017-08-11 CN CN202510270903.XA patent/CN120037367A/zh active Pending
- 2017-08-11 EP EP25225892.6A patent/EP4711008A2/en active Pending
- 2017-08-11 HU HUE20180938A patent/HUE063625T2/hu unknown
- 2017-08-11 ES ES17768863T patent/ES2821924T3/es active Active
- 2017-08-11 DK DK17768863.7T patent/DK3497132T3/da active
- 2017-08-11 PT PT201809381T patent/PT3733712T/pt unknown
- 2017-08-11 CA CA3101514A patent/CA3101514A1/en active Pending
- 2017-08-11 KR KR1020207034140A patent/KR20200136503A/ko not_active Ceased
- 2017-08-11 SI SI201730400T patent/SI3497132T1/sl unknown
- 2017-08-11 CN CN202510270924.1A patent/CN120000782A/zh active Pending
- 2017-08-11 IL IL313932A patent/IL313932A/en unknown
- 2017-08-11 IL IL276890A patent/IL276890B2/en unknown
- 2017-08-11 DK DK20180938.1T patent/DK3733712T3/da active
- 2017-08-11 SI SI201731396T patent/SI3733712T1/sl unknown
- 2017-08-11 EP EP24166956.3A patent/EP4371611A3/en active Pending
- 2017-08-11 HR HRP20201388TT patent/HRP20201388T1/hr unknown
- 2017-08-11 CN CN201780049932.7A patent/CN109641965A/zh active Pending
- 2017-08-11 PL PL20180938.1T patent/PL3733712T3/pl unknown
- 2017-08-11 CN CN202510270961.2A patent/CN120053639A/zh active Pending
- 2017-08-11 US US16/324,619 patent/US11161909B2/en active Active
- 2017-08-11 JP JP2018550539A patent/JP6851391B2/ja active Active
- 2017-08-11 RS RS20201066A patent/RS60807B1/sr unknown
- 2017-08-11 LT LTEP20180938.1T patent/LT3733712T/lt unknown
- 2017-08-15 TW TW106127565A patent/TWI752995B/zh active
-
2019
- 2019-02-12 IL IL264804A patent/IL264804B/en active IP Right Grant
-
2020
- 2020-02-07 JP JP2020019337A patent/JP7198786B2/ja active Active
- 2020-02-17 AU AU2020201112A patent/AU2020201112C1/en active Active
- 2020-09-11 CY CY20201100861T patent/CY1123350T1/el unknown
-
2021
- 2021-10-06 US US17/495,559 patent/US20220081488A1/en not_active Abandoned
-
2023
- 2023-06-08 US US18/331,701 patent/US12570754B2/en active Active
-
2024
- 2024-03-06 US US18/597,624 patent/US12338290B2/en active Active
-
2025
- 2025-05-28 US US19/221,422 patent/US20250289902A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511506A5 (https=) | ||
| JP2015187125A5 (https=) | ||
| JP2018510898A (ja) | 嘔気嘔吐を治療するためのアミスルプリドと他の制吐薬との併用 | |
| JP2011173928A5 (https=) | ||
| JP2015512392A5 (https=) | ||
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| HUE029677T2 (hu) | Készítmények centrálisan mediált émelygés és hányás kezelésére | |
| EA201590166A1 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| JP2017513809A5 (https=) | ||
| JP2018507243A5 (https=) | ||
| IL309340A (en) | Dosing regimen for missing doses of paliperidone long-acting injectable esters | |
| JP2018531605A5 (https=) | ||
| JP2020100630A5 (https=) | ||
| JP2018510894A5 (https=) | ||
| HRP20201388T1 (hr) | Režimi i postupci liječenja multiple skleroze uporabom ofatumumaba | |
| RU2007101686A (ru) | Комбинированная композиция | |
| JP2010538066A5 (https=) | ||
| Gopalakrishna et al. | Long-acting injectable aripiprazole: how might it fit in our tool box? | |
| JP2019529543A5 (https=) | ||
| JP2016505050A5 (https=) | ||
| HRP20240812T1 (hr) | Oblici doziranja i terapijska primjena l-4-klorokinurenina | |
| IL310909A (en) | Dosing regimens associated with extended release paliperidone injectable formulations | |
| JP2023020885A5 (https=) | ||
| JP2014508174A5 (https=) | ||
| JP2020506209A (ja) | 術後悪心嘔吐の救急治療 |